roxadustat

FibroGen slides after FDA posted documents ahead of AdCom meeting on Roxadustat
FibroGen slides after FDA posted documents ahead of AdCom meeting on Roxadustat
Seeking Alpha
FibroGen
FDA
roxadustat
advisory panels
chronic kidney disease
Flag link:
FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat
FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat
Endpoints
FibroGen
anemia
roxadustat
Flag link:
FibroGen shares skid lower as a surprise adcomm raises risks on roxa OK
FibroGen shares skid lower as a surprise adcomm raises risks on roxa OK
Endpoints
FibroGen
roxadustat
FDA
advisory panel
Flag link:
AstraZeneca, FibroGen's roxadustat hits snag at FDA, but analysts figure an approval's still on its way
AstraZeneca, FibroGen's roxadustat hits snag at FDA, but analysts figure an approval's still on its way
Fierce Pharma
AstraZeneca
FibroGen
roxadustat
FDA
anemia
Flag link:
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease
BioSpace
FibroGen
roxadustat
ASN
chronic kidney disease
Flag link:
5 FDA approval decisions to watch in the 4th quarter
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Flag link:
Astellas' Anemia Drug Roxadustat Shows Non-Inferiority to Amgen's Aranesp
Astellas' Anemia Drug Roxadustat Shows Non-Inferiority to Amgen's Aranesp
BioSpace
Astellas
clinical trials
roxadustat
Amgen
Aranesp
anemia
chronic kidney disease
Flag link:
Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease population
Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease population
Endpoints
FibroGen
AstraZeneca
FDA
anemia
chronic kidney disease
roxadustat
Flag link:
Data From 3 Roxadustat Trials Lead Off Kidney Week Sessions Ahead of Efficacy, Safety News
Data From 3 Roxadustat Trials Lead Off Kidney Week Sessions Ahead of Efficacy, Safety News
Managed Markets Network
nephrology
roxadustat
AstraZeneca
FibroGen
kidney disease
Flag link:
FibroGen founder Thomas Neff dies suddenly as drug he championed racks up milestones
FibroGen founder Thomas Neff dies suddenly as drug he championed racks up milestones
Fierce Pharma
FibroGen
Thomas Neff
Pharma CEOs
roxadustat
Flag link:
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
Yahoo/Zacks.com
AstraZeneca
FibroGen
China
roxadustat
chronic kidney disease
Flag link:
AstraZeneca pays Sobi $95M for priority review voucher
AstraZeneca pays Sobi $95M for priority review voucher
Fierce Biotech
AstraZeneca
FDA
Sobi
priority review vouchers
roxadustat
Flag link:
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
Flag link:
FibroGen Has The Look Of A Long-Term Biotech Winner
FibroGen Has The Look Of A Long-Term Biotech Winner
Seeking Alpha
FibroGen
roxadustat
kidney disease
Flag link:
AstraZeneca Boasts of Pipeline as Analysts See Deal Ahead
AstraZeneca Boasts of Pipeline as Analysts See Deal Ahead
Bloomberg
AstraZeneca
roxadustat
kidney disease
non-small cell lung cancer
AZD9291
Flag link: